Unpacking the ASCENT-03 Efficacy and Safety Data

Infographic

The panel takes a closer look at ASCENT-03, framing it as a study designed to test whether a TROP2-directed ADC could serve as a first-line alternative to chemotherapy. Panelists discuss the trial's primary progression-free survival endpoint and how the benefit was reflected across secondary endpoints, including duration of response and PFS2, while noting that overall survival data remain immature in the context of substantial crossover. The discussion explores consistency of benefit across clinical subgroups and recent biomarker analyses, alongside a candid review of the agent's familiar toxicity profile and how supportive care has evolved. Panelists also discuss how trial populations may differ from real-world patients, calling for clinical judgment in applying the data. The conversation closes on the importance of updated prophylaxis guidance, including growth factor and antidiarrheal support, as a way to further improve on reported tolerability. Viewers gain context for interpreting this trial in everyday practice.